---
title: "Assertio Terminates Garda Agreement, Agrees To $166.4 Mln Acquisition By Zydus Worldwide DMCC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286261460.md"
description: "Assertio Holdings, Inc. (ASRT) announced that Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd., will acquire Assertio for approximately $166.4 million in cash, or $23.50 per share. This transaction, expected to close in Q2 2026, represents a 30.6% premium over a previous offer from Garda. Assertio's board deemed the Zydus offer a \"Superior Proposal,\" leading to the termination of the Garda agreement. Following the acquisition, Assertio's stock will be delisted from Nasdaq."
datetime: "2026-05-13T12:30:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286261460.md)
  - [en](https://longbridge.com/en/news/286261460.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286261460.md)
---

# Assertio Terminates Garda Agreement, Agrees To $166.4 Mln Acquisition By Zydus Worldwide DMCC

Add  as your preferred news source on Google

 Add Now

Assertio Holdings, Inc. (ASRT), on Wednesday, announced that Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd. (ZYDUSLIFE.BO,ZYDUSLIFE.NS), agreed to acquire Assertio for approximately $166.4 million in cash, or $23.50 per share.

The transaction is expected to close in the second quarter of 2026.

The offer represents a 30.6% premium to the $18 per share all-cash transaction with GUARD.ST announced on April 8.

The offer also represents a 7.8% premium to the revised $21.80 per share Garda transaction announced on May 4.

The transaction further represents a 75.8% premium to Assertio's unaffected closing stock price on March 20.

The company also said that the board determined that the Zydus offer constituted a "Superior Proposal" under the revised Garda merger agreement and authorized the termination of the Garda agreement to enter into the Zydus transaction.

Under the agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock for $23.50 per share in cash.

Following completion of the transaction, Assertio's common stock will no longer be listed on Nasdaq.

Zydus Lifesciences closed trading 0.92% higher at INR 939.25 on the National Stock Exchange.

In the pre-market trading, Assertio is 3.68% higher at $23.38 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ASRT.US](https://longbridge.com/en/quote/ASRT.US.md)

## Related News & Research

- [Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT](https://longbridge.com/en/news/286953224.md)
- [BUZZ-Assertio Holdings rises after $166 million buyout by Zydus](https://longbridge.com/en/news/286264948.md)
- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)
- [Garda To Acquire Assertio For $21.80/shr](https://longbridge.com/en/news/285075626.md)
- [Assertio Delays Tender Offers in Pending Garda Acquisition](https://longbridge.com/en/news/285226139.md)